Bacterial Pneumonia - Pipeline Review, H1 2016

  • ID: 3775420
  • Drug Pipelines
  • 200 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Abera Bioscience AB
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • LG Life Science LTD.
  • Noxxon Pharma AG
  • SK Chemicals Co., Ltd.
  • MORE
Bacterial Pneumonia - Pipeline Review, H1 2016

Summary

‘Bacterial Pneumonia - Pipeline Review, H1 2016’, provides an overview of the Bacterial Pneumonia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bacterial Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Pneumonia and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia
- The report reviews pipeline therapeutics for Bacterial Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bacterial Pneumonia therapeutics and enlists all their major and minor projects
- The report assesses Bacterial Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bacterial Pneumonia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bacterial Pneumonia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bacterial Pneumonia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Abera Bioscience AB
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • LG Life Science LTD.
  • Noxxon Pharma AG
  • SK Chemicals Co., Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Bacterial Pneumonia Overview

Therapeutics Development

Pipeline Products for Bacterial Pneumonia - Overview

Pipeline Products for Bacterial Pneumonia - Comparative Analysis

Bacterial Pneumonia - Therapeutics under Development by Companies

Bacterial Pneumonia - Therapeutics under Investigation by Universities/Institutes

Bacterial Pneumonia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Bacterial Pneumonia - Products under Development by Companies

Bacterial Pneumonia - Products under Investigation by Universities/Institutes

Bacterial Pneumonia - Companies Involved in Therapeutics Development

Abera Bioscience AB

Actelion Ltd

Alvogen Korea Co., Ltd.

Aridis Pharmaceuticals LLC

Arsanis Biosciences GmbH

AstraZeneca Plc

Beijing Minhai Biotechnology Co., Ltd

ContraFect Corporation

Daiichi Sankyo Company, Limited

Double Bond Pharmaceutical International AB

Emergent BioSolutions Inc.

Eurocine Vaccines AB

FluGen, Inc.

GlaxoSmithKline Plc

Humabs BioMed SA

ImmunoBiology Limited

Indian Immunologicals Limited

Integrated BioTherapeutics, Inc.

Kyorin Pharmaceutical Co., Ltd.

Lascco SA

LG Life Science LTD.

Liquidia Technologies, Inc.

MedImmune, LLC

Merck & Co., Inc.

Mucosis B.V.

Noxxon Pharma AG

Panacea Biotec Limited

Prometheon Pharma, LLC

Sanofi Pasteur SA

Serum Institute of India Limited

SK Chemicals Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Valneva SE

Vaxxilon AG

Virometix AG

Walvax Biotechnology Co., Ltd.

Wellstat Vaccines, LLC

Wockhardt Limited

Bacterial Pneumonia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(cilastatin sodium + imipenem + relebactam) - Drug Profile

(Streptococcal pneumonia + typhoid) vaccine - Drug Profile

Ab-01 - Drug Profile

ACT-292706 - Drug Profile

ACT-387042 - Drug Profile

Aerucin - Drug Profile

ASN-400 - Drug Profile

AT-62aa - Drug Profile

AZ-6142 - Drug Profile

CAL-02 - Drug Profile

CB-027 - Drug Profile

cefepime + zidebactam - Drug Profile

CF-301 - Drug Profile

CF-302 - Drug Profile

CF-303 - Drug Profile

CF-309 - Drug Profile

DEF-201 - Drug Profile

doxycycline - Drug Profile

EV-035 - Drug Profile

Fab-001 - Drug Profile

GSK-2189242A - Drug Profile

KRPAM-1977X - Drug Profile

KRPAM-1977Y - Drug Profile

LBVE - Drug Profile

LCB-010371 - Drug Profile

MEDI-3902 - Drug Profile

Monoclonal Antibodies for Pneumococcus Infections - Drug Profile

Monoclonal Antibodies to Inhibit ADAM10 for Dermatology, Infectious Diseases and Respiratory Disorders - Drug Profile

Monoclonal Antibody for Staphylococcus Aureus Infections - Drug Profile

Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation and Neurodegenerative Diseases - Drug Profile

NBP-606 - Drug Profile

NOXD-21 - Drug Profile

Nucovac - Drug Profile

panobacumab - Drug Profile

PneuGEM - Drug Profile

pneumococcal (13-valent) vaccine - Drug Profile

pneumococcal (13-valent) vaccine - Drug Profile

pneumococcal (13-valent) vaccine - Drug Profile

pneumococcal (23-valent) vaccine - Drug Profile

pneumococcal (23-valent) vaccine - Drug Profile

pneumococcal [serotype 4, 6A] vaccine - Drug Profile

pneumococcal [strain TIGR4] vaccine - Drug Profile

pneumococcal vaccine - Drug Profile

pneumococcal vaccine - Drug Profile

pneumococcal vaccine - Drug Profile

pneumococcal vaccine - Drug Profile

pneumococcal vaccine - Drug Profile

pneumococcal vaccine - Drug Profile

pneumococcal vaccine - Drug Profile

pneumococcal vaccine - Drug Profile

pneumococcal vaccine - Drug Profile

PneumoMab - Drug Profile

pneumonia vaccine - Drug Profile

pneumonia vaccine - Drug Profile

pneumonia vaccine - Drug Profile

PnuBioVax - Drug Profile

PPV-23 - Drug Profile

R-10001 - Drug Profile

Recombinant Enzyme for Pseudomonas Aeruginosa Pneumonia - Drug Profile

SIILPCV-10 - Drug Profile

SM-295291 - Drug Profile

SM-369926 - Drug Profile

Small Molecule for Respiratory Tract Infections - Drug Profile

Small Molecule to Inhibit CTP synthase for Respiratory Tract Infections - Drug Profile

Small Molecules for Chlamydophila Infections - Drug Profile

Small Molecules for Streptococcus Pneumoniae Infections - Drug Profile

Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile

SRT-3025 - Drug Profile

Staphylococcus aureus (multivalent) vaccine - Drug Profile

streptococcal pneumonia vaccine - Drug Profile

Streptococcal pneumonia vaccine - Drug Profile

Streptococcal pneumonia vaccine - Drug Profile

Streptococcal pneumonia vaccine 3 - Drug Profile

Streptococcus pneumonia (whole-cell) vaccine - Drug Profile

Streptococcus pneumonia vaccine - Drug Profile

Streptococcus pneumonia vaccine - Drug Profile

Synthetic Peptides for Bacterial Infections - Drug Profile

tedizolid phosphate - Drug Profile

V-114 - Drug Profile

VMT-1 - Drug Profile

WCK-2349 - Drug Profile

WCK-4873 - Drug Profile

WCK-771 - Drug Profile

Bacterial Pneumonia - Dormant Projects

Bacterial Pneumonia - Discontinued Products

Bacterial Pneumonia - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Bacterial Pneumonia, H1 2016

Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Investigation by Universities/Institutes, H1 2016

Bacterial Pneumonia - Pipeline by Abera Bioscience AB, H1 2016

Bacterial Pneumonia - Pipeline by Actelion Ltd, H1 2016

Bacterial Pneumonia - Pipeline by Alvogen Korea Co., Ltd., H1 2016

Bacterial Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H1 2016

Bacterial Pneumonia - Pipeline by Arsanis Biosciences GmbH, H1 2016

Bacterial Pneumonia - Pipeline by AstraZeneca Plc, H1 2016

Bacterial Pneumonia - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016

Bacterial Pneumonia - Pipeline by ContraFect Corporation, H1 2016

Bacterial Pneumonia - Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Bacterial Pneumonia - Pipeline by Double Bond Pharmaceutical International AB, H1 2016

Bacterial Pneumonia - Pipeline by Emergent BioSolutions Inc., H1 2016

Bacterial Pneumonia - Pipeline by Eurocine Vaccines AB, H1 2016

Bacterial Pneumonia - Pipeline by FluGen, Inc., H1 2016

Bacterial Pneumonia - Pipeline by GlaxoSmithKline Plc, H1 2016

Bacterial Pneumonia - Pipeline by Humabs BioMed SA, H1 2016

Bacterial Pneumonia - Pipeline by ImmunoBiology Limited, H1 2016

Bacterial Pneumonia - Pipeline by Indian Immunologicals Limited, H1 2016

Bacterial Pneumonia - Pipeline by Integrated BioTherapeutics, Inc., H1 2016

Bacterial Pneumonia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016

Bacterial Pneumonia - Pipeline by Lascco SA, H1 2016

Bacterial Pneumonia - Pipeline by LG Life Science LTD., H1 2016

Bacterial Pneumonia - Pipeline by Liquidia Technologies, Inc., H1 2016

Bacterial Pneumonia - Pipeline by MedImmune, LLC, H1 2016

Bacterial Pneumonia - Pipeline by Merck & Co., Inc., H1 2016

Bacterial Pneumonia - Pipeline by Mucosis B.V., H1 2016

Bacterial Pneumonia - Pipeline by Noxxon Pharma AG, H1 2016

Bacterial Pneumonia - Pipeline by Panacea Biotec Limited, H1 2016

Bacterial Pneumonia - Pipeline by Prometheon Pharma, LLC, H1 2016

Bacterial Pneumonia - Pipeline by Sanofi Pasteur SA, H1 2016

Bacterial Pneumonia - Pipeline by Serum Institute of India Limited, H1 2016

Bacterial Pneumonia - Pipeline by SK Chemicals Co., Ltd., H1 2016

Bacterial Pneumonia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016

Bacterial Pneumonia - Pipeline by Valneva SE, H1 2016

Bacterial Pneumonia - Pipeline by Vaxxilon AG, H1 2016

Bacterial Pneumonia - Pipeline by Virometix AG, H1 2016

Bacterial Pneumonia - Pipeline by Walvax Biotechnology Co., Ltd., H1 2016

Bacterial Pneumonia - Pipeline by Wellstat Vaccines, LLC, H1 2016

Bacterial Pneumonia - Pipeline by Wockhardt Limited, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Bacterial Pneumonia - Dormant Projects, H1 2016

Bacterial Pneumonia - Dormant Projects (Contd..1), H1 2016

Bacterial Pneumonia - Dormant Projects (Contd..2), H1 2016

Bacterial Pneumonia - Dormant Projects (Contd..3), H1 2016

Bacterial Pneumonia - Dormant Projects (Contd..4), H1 2016

Bacterial Pneumonia - Dormant Projects (Contd..5), H1 2016

Bacterial Pneumonia - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Bacterial Pneumonia, H1 2016

Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Abera Bioscience AB
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • LG Life Science LTD.
  • Noxxon Pharma AG
  • SK Chemicals Co., Ltd.
  • MORE
Bacterial Pneumonia Bacterial pneumonia is an infection in one or both lungs. The bacteria cause the lung’s air sacs (alveoli) to become inflamed and engorged with pus, fluid, and cellular debris. This often impairs the body’s ability to exchange oxygen and carbon dioxide. Predisposing factors are age, long-term users of immunosuppressant drugs, chronic obstructive pulmonary disease (COPD) patients who use inhaled corticosteroids for lengthy periods and smokers. Symptoms include cough with yellow, green, or blood-tinged mucus, headache, muscle pain, breathlessness or rapid breathing, lethargy and confusion.

Bacterial Pneumonia pipeline therapeutics constitutes close to 83 molecules. Out of which approximately 70 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 7, 11, 1, 31, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 5 molecules, respectively.

Our latest report Bacterial Pneumonia – Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Bacterial Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Bacterial Pneumonia and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Abera Bioscience AB
Actelion Ltd
Alvogen Korea Co., Ltd.
Aridis Pharmaceuticals LLC
Arsanis Biosciences GmbH
AstraZeneca Plc
Beijing Minhai Biotechnology Co., Ltd
ContraFect Corporation
Daiichi Sankyo Company, Limited
Double Bond Pharmaceutical International AB
Emergent BioSolutions Inc.
Eurocine Vaccines AB
FluGen, Inc.
GlaxoSmithKline Plc
Humabs BioMed SA
ImmunoBiology Limited
Indian Immunologicals Limited
Integrated BioTherapeutics, Inc.
Kyorin Pharmaceutical Co., Ltd.
Lascco SA
LG Life Science LTD.
Liquidia Technologies, Inc.
MedImmune, LLC
Merck & Co., Inc.
Mucosis B.V.
Noxxon Pharma AG
Panacea Biotec Limited
Prometheon Pharma, LLC
Sanofi Pasteur SA
Serum Institute of India Limited
SK Chemicals Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Valneva SE
Vaxxilon AG
Virometix AG
Walvax Biotechnology Co., Ltd.
Wellstat Vaccines, LLC
Wockhardt Limited
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll